Clinical profile of a new hormone replacement therapy containing 2 mg 17β-estradiol and 10 mg dydrogesterone

Maturitas

Volumn 34, Issue 3, 2000, Pages 267-273

  Sator, Michael O ^a   Nagele, Fritz ^a   Sator, Paul ^b   Travica, Sanja ^c   Gruber, Doris ^a   Huber, Johannes C ^a  

^a Div Gynaecological Endocrinol R   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Department of Medicine   (Austria)

Author keywords

17 estradiol; Dydrogesterone; Hormone replacement therapy

Indexed keywords

DYDROGESTERONE; ESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; SCORING SYSTEM; TRANSVAGINAL ECHOGRAPHY;

ADULT; AUSTRIA; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES;

EID: 0034737371     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00110-3     Document Type: Article

References (24)

1. Hill K. The demography of menopause. Maturitas. 23:1996;113-127.
2. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151(1):1991;75-78.
3. Less B., Pugh M., Siddle N. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos. Int. 5(5):1995;344-348.
4. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Matutitas. 12:1990;171-197.
5. Martin P.L., Burnier A.M., Greaney M.O. Oral menopausal therapy using 17β-micronized estradiol. Obstet. Gynecol. 39:1972;771-774.
6. Mc Kinley S.M., Jefferys M. The menopausal syndrome. Br. J. Prev. Med. 28:1974;108-115.
7. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329:1993;753-756.
8. Callantine M.R., Martin P.L., Bolding O.T., Warner P.O., Greaney M.O. Micronized 17β-estradiol for oral estrogen therapy in menopausal women. Obstet. Gynecol. 46:1975;37-41.
9. Amy J.J. Femoston®: effects on bone and quality-of-life. Eur. Menopause J. 2(4):1995;16-22.
10. Poehlman ET. Energy, metabolism, body composition and the menopause transition. Presented at NAMS, Washington, 1994 (Abstract).
11. Hänggi W., Lippuner K., Jaeger P. Dirrerential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin. Endocrinol. 48:1998;691-699.
12. Crook D., Godsland I.F., Hull J. Hormone replacement therapy with dydrogesterone and 17β-estradiol: effects on serum lipoproteins and glucose tolerance during 24-month follow-up. Br. J. Obstet. Gynaecol. 104:1997;298-304.
13. Crook D. Multicentre evaluation of 17β-estradiol and dydrogesterone HRT on cardiovascular risk (abstract no. F 200), 8th International Congress on the Menopause, Sydney, Australia, 3-7 November, 1996.
14. Van der Mooren M.J., Demacker P.N.M., Thomas C.M.G. A 2-year study on the beneficial effects of 17β-estradiol-dydrogesterone therapy on serum lipoproteins and Lp (a) in postmenopausal women - no additional unfavourable effects of dydrogesterone. Eur. J. Obstet. Gynecol. Reprod. Biol. 52:1993;117-123.
15. Meijer S, Hamerlynck JVTH, Sauerwein HP. Effects of postmenopausal use of 17β-oestradiol and dydrogesterone on body composition (fat and water) [abstract], 7th International Congress on the Menopause, Stockholm, Sweden, 20-24 June, 1993, p. 391.
16. Bergeron C. Endometrial safety of Femoston® Eur. Menopause J. 2(4):1995;4-8.
17. The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The PEPI Trial, J Am Med Assoc 1996;275(5):370-375.
18. Schöler H.F.L., De Wachter A.M. Biological properties of 9,10-isomeric steroids. Progestational activity of 9b, 10a-steroids. Acta Endocrinol. 35:1960;188-196.
19. Gambrell R.D. Sex steroids and cancer. Obstet. Gynaecol. Clin. N. Am. 14:1987;191-206.
20. Grady D., Gebretsadik T., Kerlikowske K. et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynaecol. 85:1995;304-314.
21. Burch D.J., Spowart K.J.M., Jesinger D.K. A dose-ranging study of the use of cyclical dydrogestrone with continuous 17β-estradiol. Br. J. Obstet. Gynaecol. 102:1995;243-248.
22. Ferency A., Gelfand M.M. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas. 26:1997;219-226.
23. Al-Azzawi F., Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br. J. Obstet. Gynaecol. 101:1994;661-662.
24. Gelfand M.M., Fugere P., Bissonnette F. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology and bleeding. Menopause: J. N. Am. Menopause Soc. 4(1):1997;10-18.